{
    "clinical_study": {
        "@rank": "276",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 13, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04341935"
        },
        "id_info": {
            "org_study_id": "20200384",
            "nct_id": "NCT04341935"
        },
        "brief_title": "Effects of DPP4 Inhibition on COVID-19",
        "official_title": "Effects of DPP4 Inhibition on COVID-19 Patients With Type 2 Diabetes",
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Miami",
                "agency_class": "Other"
            }
        },
        "source": "University of Miami",
        "oversight_info": {
            "has_dmc": "No",
            "is_fda_regulated_drug": "Yes",
            "is_fda_regulated_device": "No",
            "is_us_export": "No"
        },
        "brief_summary": {
            "textblock": "The purpose of this research is to see if the DPP4 inhibitor linagliptin, an oral medication\n      commonly used to treat type 2 diabetes,can help with diabetes control and reduce the severity\n      of the COVID-19 infection"
        },
        "overall_status": "Not yet recruiting",
        "start_date": {
            "@type": "Anticipated",
            "#text": "April 30, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "September 30, 2020"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "June 30, 2020"
        },
        "phase": "Phase 4",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Randomized",
            "intervention_model": "Parallel Assignment",
            "primary_purpose": "Treatment",
            "masking": "None (Open Label)"
        },
        "primary_outcome": {
            "measure": "Changes in Glucose Llevels",
            "time_frame": "Baseline, up to 2 weeks",
            "description": "Change in glucose control will be assessed via glucose levels obtained from blood serum samples"
        },
        "secondary_outcome": [
            {
                "measure": "Changes in SpO2 levels",
                "time_frame": "Baseline, up to 2 weeks",
                "description": "changes in SpO2 will be measured with a Pulseimetry, an indirect, non-invasive method"
            },
            {
                "measure": "Changes in Interleukin 6 (IL6)",
                "time_frame": "Baseline, up to 2 weeks",
                "description": "Changes in IL 6 will be assessed from blood serum samples"
            },
            {
                "measure": "Changes in chest structures",
                "time_frame": "Baseline, up to 2 weeks",
                "description": "Changes in Chest radiography (X-ray)"
            }
        ],
        "number_of_arms": "2",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "20"
        },
        "condition": [
            "Coronavirus Infection",
            "Type 2 Diabetes"
        ],
        "arm_group": [
            {
                "arm_group_label": "DPP4 group",
                "arm_group_type": "Experimental",
                "description": "Participants in the Dipeptidyl Peptidase 4 (DPP4) group will receive Linagliptin in addition to standard of care insulin regimen as per hospital protocol during hospitalization for up to 14 days"
            },
            {
                "arm_group_label": "Control group",
                "arm_group_type": "Active Comparator",
                "description": "Participants in the control group will receive only the standard of care insulin regimen as per hospital protocol during hospitalization for up to 14 days"
            }
        ],
        "intervention": [
            {
                "intervention_type": "Drug",
                "intervention_name": "Linagliptin",
                "description": "5 mg Linagliptin administered by mouth once daily",
                "arm_group_label": "DPP4 group",
                "other_name": "Tradjenta"
            },
            {
                "intervention_type": "Drug",
                "intervention_name": "Insulin regimen",
                "description": "Standard of care insulin regimen as per hospital protocol",
                "arm_group_label": "Control group"
            }
        ],
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 2 Diabetes Mellitus (T2DM) as per American Diabetes Association (ADA) guidelines\n\n          -  Age \u2265 18\n\n          -  Confirmed COVID-19\n\n          -  Mild COVID-19 defined as any of the following: fever, malaise, cough, headache, sore\n             throat, myalgia, nasal congestion, diarrhea\n\n          -  Moderate COVID-19 is defined as > 2 of the following in non-intubated patients: any\n             symptom of mild disease, radiographic imaging (chest x-ray or lung ultrasound) with\n             bilateral ground glass opacities or bilateral consolidations, SpO2 <90% up to 5L Nasal\n             Cannula (NC)\n\n          -  No additional signs or symptoms of severe COVID-19.\n\n        Exclusion Criteria:\n\n          -  Type 1 Diabetes Mellitus (T1DM) diabetes, as per ADA guidelines\n\n          -  History of Diabetic Ketoacidosis (DKA)\n\n          -  History of acute pancreatitis\n\n          -  Chronic or Acute Renal Failure with Estimated Glomerular Filtration Rate (eGFR) < 30\n             ml/min/1.73 m2\n\n        Exclusion Criteria:\n\n        T1DM diabetes, as per ADA guidelines, History of DKA, History of acute pancreatitis;\n        Chronic or Acute Renal Failure with eGFR < 30 ml/min/1.73 m2"
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "N/A",
            "healthy_volunteers": "No"
        },
        "overall_official": {
            "last_name": "Gianluca Iacobellis, MD PhD",
            "role": "Principal Investigator",
            "affiliation": "University of Miami"
        },
        "overall_contact": {
            "last_name": "Gianluca Iacobellis, MD PhD",
            "phone": "3052433636",
            "email": "giacobellis@med.miami.edu"
        },
        "location": {
            "facility": {
                "name": "University of Miami",
                "address": {
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33136",
                    "country": "United States"
                }
            }
        },
        "location_countries": {
            "country": "United States"
        },
        "results_reference": [
            {
                "citation": "Vankadari N, Wilce JA. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect. 2020 Mar 17;9(1):601-604. doi: 10.1080/22221751.2020.1739565. eCollection 2020.",
                "PMID": "32178593"
            },
            {
                "citation": "Iacobellis G. COVID-19 and diabetes: Can DPP4 inhibition play a role? Diabetes Res Clin Pract. 2020 Mar 26;162:108125. doi: 10.1016/j.diabres.2020.108125. [Epub ahead of print]",
                "PMID": "32224164"
            }
        ],
        "verification_date": "April 2020",
        "study_first_submitted": "April 6, 2020",
        "study_first_submitted_qc": "April 7, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "April 10, 2020"
        },
        "last_update_submitted": "April 7, 2020",
        "last_update_submitted_qc": "April 7, 2020",
        "last_update_posted": {
            "@type": "Actual",
            "#text": "April 10, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Principal Investigator",
            "investigator_affiliation": "University of Miami",
            "investigator_full_name": "Gianluca Iacobellis",
            "investigator_title": "Professor of Medicine"
        },
        "keyword": [
            "COVID-19",
            "SARS-Cov 2",
            "DPP4",
            "Type 2 diabetes"
        ],
        "condition_browse": {
            "mesh_term": [
                "Coronavirus Infections",
                "Severe Acute Respiratory Syndrome",
                "Diabetes Mellitus, Type 2"
            ]
        },
        "intervention_browse": {
            "mesh_term": [
                "Insulin",
                "Insulin, Globin Zinc",
                "Linagliptin"
            ]
        },
        "patient_data": {
            "sharing_ipd": "No"
        }
    }
}